93 results on '"Kass-Hout T"'
Search Results
2. E-099 Outcomes after middle meningeal artery embolization using n-butyl-2-cyanoacrylate for subdural hematomas: a case-series
- Author
-
Carrión-Penagos, J, primary, Morsi, R, additional, Tarabichi, A, additional, Thind, S, additional, Kothari, S, additional, Desai, H, additional, Coleman, E, additional, Brorson, J, additional, Mendelson, S, additional, Prabhakaran, S, additional, Mansour, A, additional, and Kass-Hout, T, additional
- Published
- 2023
- Full Text
- View/download PDF
3. E-250 eTICI 2b67–3 is an optimal reperfusion benchmark and is achieved on the first pass in two out of every three cases in the NeVa clear study
- Author
-
Yoo, A, primary, Geyik, S, additional, Froehler, M, additional, Maurer, C, additional, Kass-Hout, T, additional, Zaidat, O, additional, Nogueira, R, additional, Hanel, R, additional, Pierot, L, additional, Spelle, L, additional, Lopes, D, additional, Hassan, A, additional, Audrius, Š, additional, Lin, E, additional, Ribó, M, additional, Blasco, J, additional, Taqi, M, additional, Badruddin, A, additional, Siddiqui, A, additional, Miller, T, additional, Hussain, S, additional, Haussen, D, additional, Woodward, K, additional, Groden, C, additional, Consoli, A, additional, Chaudry, I, additional, Ramsey, C, additional, Maud, A, additional, Bentley, J, additional, Brinjikji, W, additional, Bajrami, A, additional, Sahnoun, M, additional, Fiehler, J, additional, and Gupta, R, additional
- Published
- 2023
- Full Text
- View/download PDF
4. P-010 Endovascular thrombectomy with or without bridging thrombolysis in acute ischemic stroke: a cost-effectiveness analysis
- Author
-
Morsi, R, primary, Zhang, Y, additional, Zhu, M, additional, Xie, S, additional, Carrión-Penagos, J, additional, Desai, H, additional, Tannous, E, additional, Kothari, S, additional, Khamis, A, additional, Darzi, A, additional, Tarabichi, A, additional, Bastin, R, additional, Hneiny, L, additional, Thind, S, additional, Siegler, J, additional, Coleman, E, additional, Mendelson, S, additional, Mansour, A, additional, Prabhakaran, S, additional, and Kass-Hout, T, additional
- Published
- 2023
- Full Text
- View/download PDF
5. P-003 The zoomTMRDL radial access system for neurointervention: an early single-center experience
- Author
-
Morsi, R, primary, Kothari, S, additional, Thind, S, additional, Desai, H, additional, Polster, S, additional, Goldenberg, F, additional, Coleman, E, additional, Brorson, J, additional, Mendelson, S, additional, Mansour, A, additional, Prabhakaran, S, additional, and Kass-Hout, T, additional
- Published
- 2023
- Full Text
- View/download PDF
6. E-028 Middle meningeal artery embolization using zoomTM45 aspiration catheter: an early single-center experience
- Author
-
Thind, S, primary, Morsi, R, additional, Carrión-Penagos, J, additional, Desai, H, additional, Kothari, S, additional, Polster, S, additional, Siegler, J, additional, Coleman, E, additional, Mendelson, S, additional, Mansour, A, additional, Hurley, M, additional, Prabhakaran, S, additional, and Kass-Hout, T, additional
- Published
- 2023
- Full Text
- View/download PDF
7. E-122 Endovascular embolization of penetrating vessel injury using N-butyl cyanoacrylate
- Author
-
Morsi, R, primary, Carrión-Penagos, J, additional, Thind, S, additional, Mansour, A, additional, Kramer, C, additional, Lazaridis, C, additional, Goldenberg, F, additional, Prabhakaran, S, additional, and Kass-Hout, T, additional
- Published
- 2022
- Full Text
- View/download PDF
8. E-137 Endovascular therapy delay for acute large vessel occlusion is associated with worse functional outcome and increased mortality
- Author
-
Carrion-Penagos, J, primary, Morsi, R, additional, Thind, S, additional, Coleman, E, additional, Brorson, J, additional, McKoy, C, additional, Mendelson, S, additional, Prabhakaran, S, additional, Mansour, A, additional, and Kass-Hout, T, additional
- Published
- 2022
- Full Text
- View/download PDF
9. P-032 Underlying intracranial atherosclerotic disease is associated with worse outcomes in acute large vessel occlusion undergoing endovascular therapy
- Author
-
Thind, S, primary, Morsi, R, additional, Karrison, T, additional, Coleman, E, additional, Brorson, J, additional, McKoy, C, additional, Mendelson, S, additional, Mansour, A, additional, Prabhakaran, S, additional, and Kass-Hout, T, additional
- Published
- 2022
- Full Text
- View/download PDF
10. E-186 Middle meningeal artery embolization withn-butyl-2-cyanoacrylate (NBCA) for management of chronic subdural hematoma, a single center experience
- Author
-
Carrion Penagos, J, primary, Morsi, R, additional, Thind, S, additional, Mansour, A, additional, Kramer, C, additional, Lazaridis, C, additional, Goldenberg, F, additional, Prabhakaran, S, additional, and Kass-Hout, T, additional
- Published
- 2022
- Full Text
- View/download PDF
11. E-058 An alternative reduced dose regimen of ticagrelor for neuroendovascular patients
- Author
-
Thind, S, primary, Morsi, R, additional, Kass-Hout, O, additional, Stern, J, additional, Tangonan, R, additional, Kass-Hout, T, additional, and Guterman, L, additional
- Published
- 2022
- Full Text
- View/download PDF
12. O-068 Direct mechanical thrombectomy with or without bridging thrombolysis in patients with acute ischemic stroke: a systematic review and meta-analysis of randomized trials
- Author
-
Morsi, R, primary, Carrión-Penagos, J, additional, Desai, H, additional, Tannous, E, additional, Kothari, S, additional, Khamis, A, additional, Tarabichi, A, additional, Bastin, R, additional, Hneiny, L, additional, Thind, S, additional, Coleman, E, additional, Brorson, J, additional, Mendelson, S, additional, Mansour, A, additional, Prabhakaran, S, additional, and Kass-Hout, T, additional
- Published
- 2022
- Full Text
- View/download PDF
13. Sensory Guillain–Barré syndrome after Campylobacter jejuni infection
- Author
-
Rajabally, Y. A., Kass-Hout, T., Wilson, P., and Damian, M. S.
- Published
- 2007
14. Social media in public health
- Author
-
Kass-Hout, T. A., primary and Alhinnawi, H., additional
- Published
- 2013
- Full Text
- View/download PDF
15. E-019 Clinical, Angiographic, and Radiographic Outcomes Differences Amongst Mechanical Thrombectomy Devices: Initial Experience of a Large-Volume Centre
- Author
-
Kass-Hout, T, primary, Kass-Hout, O, additional, Sun, C, additional, Gupta, R, additional, and Nogueira, R, additional
- Published
- 2013
- Full Text
- View/download PDF
16. O-024 A Cost-Effectiveness Analysis of Mechanical Thrombectomy for Acute Ischaemic Stroke in the Stent-Retriever ERA
- Author
-
Kass-Hout, T, primary, Kass-Hout, O, additional, Sun, C, additional, Gupta, R, additional, and Nogueira, R, additional
- Published
- 2013
- Full Text
- View/download PDF
17. O-028 Outcomes in Patients with Acute Ischaemic Stroke from Proximal Intracranial Vessel Occlusion and NIHSS Score Below 8
- Author
-
Mokin, M, primary, Masud, M, additional, Dumont, T, additional, Kass-Hout, T, additional, Snyder, K, additional, Siddiqui, A, additional, and Levy, E, additional
- Published
- 2013
- Full Text
- View/download PDF
18. Periprocedural antithrombotic strategies in acute ischemic stroke interventional therapy
- Author
-
Nahab, F., primary, Kass-Hout, T., additional, and Shaltoni, H. M., additional
- Published
- 2012
- Full Text
- View/download PDF
19. E-074 Intravenous thrombolysis and endovascular therapy for acute ischemic stroke with internal carotid artery occlusion: a systematic review of clinical outcomes
- Author
-
Mokin, M, primary, Kass-Hout, T, additional, Kass-Hout, O, additional, Dumont, T, additional, Kan, P, additional, Snyder, K, additional, Siddiqui, A, additional, and Levy, E, additional
- Published
- 2012
- Full Text
- View/download PDF
20. E-071 CT perfusion as a tool to predict the risk of hemorrhagic transformation in ischemic stroke treated with tissue plasminogen activator: a single center experience
- Author
-
Kass-Hout, T, primary, Kass-Hout, O, additional, Al Masry, M, additional, Mokin, M, additional, Wack, D, additional, Nourollahzadeh, E, additional, Siddiqui, A, additional, Levy, E, additional, and Synder, K, additional
- Published
- 2012
- Full Text
- View/download PDF
21. E-078 Acute stroke intervention with solitaire stent: a meta-analysis
- Author
-
Dumont, T, primary, Kass-Hout, T, additional, Eller, J, additional, Siddiqui, A, additional, and Levy, E, additional
- Published
- 2012
- Full Text
- View/download PDF
22. E-072 Wake up symptomatic stroke in acute brain ischemia (WASSABI) clinical trial
- Author
-
Kass-Hout, T, primary, Kass-Hout, O, additional, Mokin, M, additional, Al Masry, M, additional, Nourollahzadeh, E, additional, Siddiqui, A, additional, Levy, E, additional, and Synder, K, additional
- Published
- 2012
- Full Text
- View/download PDF
23. P-045 The role of bridging with intravenous thrombolysis in endovascular therapy of acute ischemic stroke
- Author
-
Kass-Hout, O, primary, Kass-Hout, T, additional, Mokin, M, additional, Siddiqui, A, additional, Levy, E, additional, and Synder, K, additional
- Published
- 2012
- Full Text
- View/download PDF
24. P-046 Correlation between recanalization rate and good clinical outcome in acute ischemic stroke, a meta-analysis
- Author
-
Nourollahzadeh, E, primary, Kass-Hout, O, additional, Mokin, M, additional, Aliotta, R, additional, Synder, K, additional, Siddiqui, A, additional, Levy, E, additional, and Kass-Hout, T, additional
- Published
- 2012
- Full Text
- View/download PDF
25. P-005 Is bridging with intravenous thrombolysis of any benefit in endovascular therapy of acute ischemic stroke?
- Author
-
Kass-Hout, T., primary, Mokin, M., additional, Kass-Hout, O., additional, Darkhabani, M., additional, Orion, D., additional, Jahshan, S., additional, Yashar, P., additional, Levy, E., additional, Siddiqui, A., additional, and Snyder, K., additional
- Published
- 2011
- Full Text
- View/download PDF
26. A Scoring System for Ascertainment of Incident Stroke; the Risk Index Score (RISc)
- Author
-
Moyé, L. A., primary, Smith, M. A., primary, Morgenstern, L. B., primary, and Kass-Hout, T. A., additional
- Published
- 2006
- Full Text
- View/download PDF
27. A scoring system for ascertainment of incident stroke; the Risk Index Score (RISc).
- Author
-
Kass-Hout, T. A., Moyé, L. A., Smith, M. A., Morgenstern, L. B., and Moyé, L A
- Subjects
CEREBROVASCULAR disease diagnosis ,MEDICAL model ,CLINICAL epidemiology ,MEDICAL records ,INTEGRATED circuits ,MEDICAL informatics ,MEDICAL record linkage ,CEREBROVASCULAR disease patients ,METHODOLOGY ,ALGORITHMS ,AUDITING ,COMPARATIVE studies ,COMPUTERS ,FORECASTING ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RESEARCH funding ,RISK assessment ,STROKE ,EVALUATION research ,RANDOMIZED controlled trials - Abstract
Objectives: The main objective of this study was to develop and validate a computer-based statistical algorithm that could be translated into a simple scoring system in order to ascertain incident stroke cases using hospital admission medical records data.Methods: The Risk Index Score (RISc) algorithm was developed using data collected prospectively by the Brain Attack Surveillance in Corpus Christi (BASIC) project, 2000. The validity of RISc was evaluated by estimating the concordance of scoring system stroke ascertainment to stroke ascertainment by physician and/or abstractor review of hospital admission records.Results: RISc was developed on 1718 randomly selected patients (training set) and then statistically validated on an independent sample of 858 patients (validation set). A multivariable logistic model was used to develop RISc and subsequently evaluated by goodness-of-fit and receiver operating characteristic (ROC) analyses. The higher the value of RISc, the higher the patient's risk of potential stroke. The study showed RISc was well calibrated and discriminated those who had potential stroke from those that did not on initial screening.Conclusion: In this study we developed and validated a rapid, easy, efficient, and accurate method to ascertain incident stroke cases from routine hospital admission records for epidemiologic investigations. Validation of this scoring system was achieved statistically; however, clinical validation in a community hospital setting is warranted. [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
28. Information and decision support systems
- Author
-
Hudspeth, W., Reisen, W. K., Barker, C. M., Kramer, V., MIHAELA CAIAN, Crăciunescu, V., Brown, H. E., Comrie, A. C., Zelicoff, A., Ward, T. G., Ragain, R. M., Simpson, G., Stanhope, W., Kass-Hout, T. A., Scharl, A., Sonricker, A. L., and Brownstein, J. S.
29. Thrombectomy for Stroke With Large Infarct on Noncontrast CT: The TESLA Randomized Clinical Trial.
- Author
-
Yoo AJ, Zaidat OO, Sheth SA, Rai AT, Ortega-Gutierrez S, Given CA 2nd, Zaidi SF, Grandhi R, Cuellar H, Mokin M, Katz JM, Alshekhlee A, Taqi MA, Ansari SA, Siddiqui AH, Barazangi N, English JD, Maud A, Kirmani J, Gupta R, Yavagal DR, Tarpley J, Pandya DJ, Cress MC, Dharmadhikari S, Asif KS, Kass-Hout T, Puri AS, Janjua N, Majjhoo AQ, Badruddin A, Edgell RC, Khatri R, Morgan L, Razak A, Zha A, Khandelwal P, Mueller-Kronast N, Rivet DJ, Wolfe T, Snelling B, Sultan-Qurraie A, Lin SP, Khangura R, Spiotta AM, Bhuva P, Salazar-Marioni S, Lin E, Tarabishy AR, Samaniego EA, Kolikonda MK, Jumaa MA, Reddy VK, Sharma P, Berkhemer OA, van Doormaal PJ, van Es ACGM, van Zwam WH, Emmer BJ, Beenen LF, Majoie CBLM, Buderer N, Detry MA, Bosse A, Graves TL, Saunders C, Elijovich L, Jadhav A, Patterson M, Slight H, Below K, and Al Kasab S
- Abstract
Importance: Recent large infarct thrombectomy trials used heterogeneous imaging modalities and time windows for patient selection. Noncontrast computed tomographic (CT) scan is the most common stroke imaging approach. It remains uncertain whether thrombectomy is effective for patients with large infarcts identified using noncontrast CT alone within 24 hours of stroke onset., Objective: To evaluate the effect of thrombectomy in patients with a large infarct on a noncontrast CT scan within 24 hours of onset., Design, Setting, and Participants: Open-label, blinded-end point, bayesian-adaptive randomized trial with interim analyses for early stopping (futility or success) or population enrichment, which was conducted at 47 US academic and community-based stroke thrombectomy centers. Three hundred patients presenting within 24 hours with anterior-circulation, large-vessel occlusion and large infarct on noncontrast CT scan, with Alberta Stroke Program Early CT Scores of 2 to 5, were randomized to undergo thrombectomy or usual care. Enrollment occurred July 16, 2019 to October 17, 2022; final follow-up, January 25, 2023., Intervention: The intervention patients (n = 152) underwent endovascular treatment using standard thrombectomy devices and usual medical care. Control patients (n = 148) underwent usual medical care alone., Main Outcomes and Measures: The primary efficacy end point was improvement in 90-day functional outcome measured using mean utility-weighted modified Rankin Scale (UW-mRS) scores (range, 0 [death or severe disability] to 10 [no symptoms]; minimum clinically important difference, 0.3). A bayesian model determined the posterior probability that the intervention would be superior to usual care; statistical significance was a 1-sided posterior probability of .975 or more. The primary adverse event end point was 90-day mortality; secondary adverse event end points included symptomatic intracranial hemorrhage and radiographic intracranial hemorrhage., Results: The trial enrolled 300 patients (152 intervention, 148 control; 138 females [46%]; median age, 67 years), without early stopping or enrichment; 297 patients completed the 90-day follow-up. The mean (SD) 90-day UW-mRS score was 2.93 (3.39) for the intervention group vs 2.27 (2.98) for the control group with an adjusted difference of 0.63 (95% credible interval [CrI], -0.09 to 1.34; posterior probability for superiority of thrombectomy, .96). The 90-day mortality was similar between groups: 35.3% (53 of 150) for the intervention group vs 33.3% (49 of 147) for the control group. Six of 151 patients (4.0%) in the intervention group and 2 of 149 (1.3%) in the control group experienced 24-hour symptomatic intracranial hemorrhage. Fourteen patients of 148 (9.5%) in the intervention group vs 4 of 146 (2.7%) in the control group experienced parenchymal hematoma type 1 hemorrhages; 14 (9.5%) in the intervention group vs 5 (3.4%) in the control group experienced parenchymal hematoma type 2 hemorrhages; and 24 (16.2%) in the intervention group vs 9 (6.2%) in the control group experienced subarachnoid hemorrhages., Conclusions and Relevance: Among patients with a large infarct on noncontrast CT within 24 hours, thrombectomy did not demonstrate improvement in functional outcomes. But the width of the credible interval around the effect estimate includes the possibility of both no important effect and a clinically relevant benefit, so the potential role of thrombectomy with this imaging approach and time window will likely require additional study., Trial Registration: ClinicalTrials.gov Identifier: NCT03805308.
- Published
- 2024
- Full Text
- View/download PDF
30. Isolated Thoracic Anterior Spinal Artery Aneurysm in a Patient With Autoimmune Disease: A Case Report.
- Author
-
Ahmadpour A, Morsi RZ, Al-Salihi MM, and Kass-Hout T
- Abstract
This case report describes a rare presentation of a mycotic anterior spinal artery aneurysm of the thoracic spine presenting as a subarachnoid hemorrhage. Isolated anterior spinal artery aneurysms are exceedingly rare. While this condition can occur in the setting of an underlying infection that may lead to shock, other signs and symptoms of the infection itself typically manifest before the development of the aneurysm and subsequent hemorrhage. We present a case of a 30-year-old male who presented with acute-onset bilateral lower extremity motor paraplegia and was found to have diffuse subarachnoid hemorrhage related to an isolated thoracic anterior spinal artery aneurysm, which was believed to be mycotic in origin. Spinal angiogram revealed evidence of an aneurysm originating from the anterior spinal artery at the T11-T12 level, contributing to diffuse subarachnoid hemorrhage of the spinal cord. The patient was followed closely and exhibited progressive improvement in motor function. Magnetic resonance imaging performed two weeks later revealed decreased intrathecal hemorrhage, mild spinal cord edema, and a reduction in the discrete visualization of the anterior spinal artery aneurysm. We present a unique case of an isolated anterior spinal artery aneurysm in the thoracic spine presenting with subarachnoid hemorrhage. This case is distinctive in that the clinical presentation and radiographic findings strongly suggest a mycotic etiology for the aneurysm, despite the absence of definitive histopathologic confirmation. To our knowledge, this is the first reported case of an isolated thoracic ASA aneurysm suspected to be mycotic in origin., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Ahmadpour et al.)
- Published
- 2024
- Full Text
- View/download PDF
31. Endovascular thrombectomy for large ischemic strokes: An updated living systematic review and meta-analysis of randomized clinical trials.
- Author
-
Morsi RZ, Elfil M, Ghaith HS, Aladawi M, Elmashad A, Kothari S, Desai H, Ghozy S, Prabhakaran S, Amuluru K, Gandhi CD, Kass-Hout T, and Al-Mufti F
- Subjects
- Humans, Endovascular Procedures methods, Ischemic Stroke surgery, Ischemic Stroke therapy, Randomized Controlled Trials as Topic methods, Thrombectomy methods
- Abstract
Background: Recent studies indicate endovascular thrombectomy (EVT) as a safe, effective treatment for acute ischemic stroke (AIS) with large ischemic regions. Our study updates an ongoing living systematic review and meta-analysis of randomized controlled trials (RCTs) comparing outcomes of EVT to medical management only., Methods: We searched MEDLINE, EMBASE, and the Cochrane Library for RCTs comparing EVT to medical management in AIS patients with large ischemic areas. Using fixed-effect models, we conducted a meta-analysis to compare functional independence, mortality, and symptomatic intracranial hemorrhage (sICH) between EVT and standard medical management. We evaluated bias risk with the Cochrane tool and graded the certainty of evidence using the GRADE approach., Results: Of 1363 new citations, we included six RCTs with a total of 1876 patients. We found low-certainty evidence of improved functional independence (risk difference [RD] 29.9%, 95% CI 17.2% to 46.9%), increase in sICH (RD 2.6%, 95% CI 0.3% to 6.4%), and a non-significant decrease in mortality (RD -1.8%, 95% CI -3.9% to 0.6%) for AIS patients with large infarcts who underwent EVT compared to medical management only., Conclusion: Our revised meta-analysis suggests low-certainty evidence that there is improved functional independence, a non-significant decrease in mortality, and an increase in sICH among AIS patients with large infarcts who undergo EVT compared to those receiving medical management alone., Systematic Review Protocol Registration: PROSPERO (CRD42023398742)., Competing Interests: Declaration of competing interest All authors reported no conflicts of interest., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
32. Early single-center experience with middle meningeal artery embolization using Zoom ™ 45 Catheter.
- Author
-
Morsi RZ, Thind S, Baskaran A, Rana R, Carrión-Penagos J, Desai H, Kothari SA, Chahine A, Zakaria J, Polster SP, Siegler JE, Mendelson SJ, Mansour A, Hurley MC, Prabhakaran S, and Kass-Hout T
- Abstract
Background: Middle meningeal artery (MMA) embolization for subdural hematomas (SDH) and dural arteriovenous fistulas (dAVFs) has gained momentum in the neuroendovascular space. However, there is variability in the technique for safe and effective embolization. The aim of this report is to describe the technical feasibility and clinical performance of using Zoom
™ 45 catheter for MMA access to facilitate embolization., Methods: We analyzed all cases of MMA embolization in which the Zoom™ 45 catheter was used and performed in our institution from February 2021 to March 2023 for SDH and dAVFs., Results: A total of 32 patients were included. Mean age was 64.0 ± 18.0 years, 75.0% (4/32) were male, and 56.7% (17/30), were black. The technical success was achieved in 93.8% (30/32) of cases, with selective embolization utilizing microcatheter directly into frontal and parietal branches for most patients (96.9%, 31/32). Identification of dangerous collaterals, such as lacrimal and petrous branches, prior to embolization, was achieved in most patients (96.9%, 31/32). Bilateral MMA embolization was done in 50.0% (16/32) of patients. The transradial approach and transfemoral approach were used in 53.1% (17/32) and 46.9% (15/32) of patients, respectively. The most common embolization material was n-butyl cyanoacrylate (84.4%, 27/32). There were no access site complications or complications related to the MMA embolization procedures and used devices., Conclusions: The use of Zoom™ 45 Catheter seems to be technically feasible, safe, and effective for facilitating MMA access for embolization in the context of SDH and dAVFs., Competing Interests: Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.- Published
- 2024
- Full Text
- View/download PDF
33. Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study.
- Author
-
Yaghi S, Shu L, Mandel D, Leon Guerrero CR, Henninger N, Muppa J, Affan M, Ul Haq Lodhi O, Heldner MR, Antonenko K, Seiffge D, Arnold M, Salehi Omran S, Crandall R, Lester E, Lopez Mena D, Arauz A, Nehme A, Boulanger M, Touze E, Sousa JA, Sargento-Freitas J, Barata V, Castro-Chaves P, Brito MT, Khan M, Mallick D, Rothstein A, Khazaal O, Kaufmann JE, Engelter ST, Traenka C, Aguiar de Sousa D, Soares M, Rosa S, Zhou LW, Gandhi P, Field TS, Mancini S, Metanis I, Leker RR, Pan K, Dantu V, Baumgartner K, Burton T, Von Rennenberg R, Nolte CH, Choi R, MacDonald J, Bavarsad Shahripour R, Guo X, Ghannam M, Almajali M, Samaniego EA, Sanchez S, Rioux B, Zine-Eddine F, Poppe A, Fonseca AC, Baptista MF, Cruz D, Romoli M, De Marco G, Longoni M, Keser Z, Griffin K, Kuohn L, Frontera J, Amar J, Giles J, Zedde M, Pascarella R, Grisendi I, Nzwalo H, Liebeskind DS, Molaie A, Cavalier A, Kam W, Mac Grory B, Al Kasab S, Anadani M, Kicielinski K, Eltatawy A, Chervak L, Chulluncuy-Rivas R, Aziz Y, Bakradze E, Tran TL, Rodrigo-Gisbert M, Requena M, Saleh Velez F, Ortiz Gracia J, Mudassani V, de Havenon A, Vishnu VY, Yaddanapudi S, Adams L, Browngoehl A, Ranasinghe T, Dunston R, Lynch Z, Penckofer M, Siegler J, Mayer S, Willey J, Zubair A, Cheng YK, Sharma R, Marto JP, Mendes Ferreira V, Klein P, Nguyen TN, Asad SD, Sarwat Z, Balabhadra A, Patel S, Secchi T, Martins S, Mantovani G, Kim YD, Krishnaiah B, Elangovan C, Lingam S, Quereshi A, Fridman S, Alvarado A, Khasiyev F, Linares G, Mannino M, Terruso V, Vassilopoulou S, Tentolouris V, Martinez-Marino M, Carrasco Wall V, Indraswari F, El Jamal S, Liu S, Alvi M, Ali F, Sarvath M, Morsi RZ, Kass-Hout T, Shi F, Zhang J, Sokhi D, Said J, Simpkins AN, Gomez R, Sen S, Ghani M, Elnazeir M, Xiao H, Kala N, Khan F, Stretz C, Mohammadzadeh N, Goldstein E, and Furie K
- Subjects
- Humans, Platelet Aggregation Inhibitors therapeutic use, Anticoagulants therapeutic use, Fibrinolytic Agents therapeutic use, Retrospective Studies, Hemorrhage chemically induced, Arteries, Treatment Outcome, Carotid Artery, Internal, Dissection complications, Carotid Artery, Internal, Dissection drug therapy, Stroke epidemiology, Stroke etiology, Stroke prevention & control, Ischemic Stroke drug therapy, Aortic Dissection, Atrial Fibrillation complications
- Abstract
Background: Small, randomized trials of patients with cervical artery dissection showed conflicting results regarding optimal stroke prevention strategies. We aimed to compare outcomes in patients with cervical artery dissection treated with antiplatelets versus anticoagulation., Methods: This is a multicenter observational retrospective international study (16 countries, 63 sites) that included patients with cervical artery dissection without major trauma. The exposure was antithrombotic treatment type (anticoagulation versus antiplatelets), and outcomes were subsequent ischemic stroke and major hemorrhage (intracranial or extracranial hemorrhage). We used adjusted Cox regression with inverse probability of treatment weighting to determine associations between anticoagulation and study outcomes within 30 and 180 days. The main analysis used an as-treated crossover approach and only included outcomes occurring with the above treatments., Results: The study included 3636 patients (402 [11.1%] received exclusively anticoagulation and 2453 [67.5%] received exclusively antiplatelets). By day 180, there were 162 new ischemic strokes (4.4%) and 28 major hemorrhages (0.8%); 87.0% of ischemic strokes occurred by day 30. In adjusted Cox regression with inverse probability of treatment weighting, compared with antiplatelet therapy, anticoagulation was associated with a nonsignificantly lower risk of subsequent ischemic stroke by day 30 (adjusted hazard ratio [HR], 0.71 [95% CI, 0.45-1.12]; P =0.145) and by day 180 (adjusted HR, 0.80 [95% CI, 0.28-2.24]; P =0.670). Anticoagulation therapy was not associated with a higher risk of major hemorrhage by day 30 (adjusted HR, 1.39 [95% CI, 0.35-5.45]; P =0.637) but was by day 180 (adjusted HR, 5.56 [95% CI, 1.53-20.13]; P =0.009). In interaction analyses, patients with occlusive dissection had significantly lower ischemic stroke risk with anticoagulation (adjusted HR, 0.40 [95% CI, 0.18-0.88]; P
interaction =0.009)., Conclusions: Our study does not rule out the benefit of anticoagulation in reducing ischemic stroke risk, particularly in patients with occlusive dissection. If anticoagulation is chosen, it seems reasonable to switch to antiplatelet therapy before 180 days to lower the risk of major bleeding. Large prospective studies are needed to validate our findings., Competing Interests: Disclosures Disclosures provided by Dr Nguyen in compliance with American Heart Association annual Journal Editor Disclosure Questionnaire are available at https://www.ahajournals.org/editor-coi-disclosures. Dr Arnold reports compensation from Boehringer Ingelheim, AstraZeneca, Bayer, Bristol-Myers Squibb, Covidien, Daiichi Sankyo, Novartis, Sanofi, Pfizer, Medtronic, Novo Nordisk, and Amgen for consultant services. Dr Lester reports a provisional patent for Methods and compositions for disrupting tau aggregates. Dr Touze reports compensation from Elsevier for other services and employment by Caen. J.E. Kaufman reports grants from Goldschmidt Jacobson-Stiftung. Dr Traenka reports travel support from Bayer Healthcare. Dr Aguiar de Sousa reports compensation from Daiichi Sankyo, Bayer, AstraZeneca, Johnson & Johnson, and Fundação Bial for other services; compensation from the University of British Columbia for data and safety monitoring services; compensation from Organon & Co for consultant services. Dr Rosa reports grants from Merck Sharp & Dohme Corporation. Dr Field reports compensation from HLS Therapeutics, AstraZeneca Canada, and Roche for consultant services; service as a board member for Destine Health; and compensation from the Canadian Medical Protective Association for expert witness services; and grants from Bayer. Dr Leker reports compensation from Medtronic, Ischemaview, Bayer, Abbott Diabetes Care, Biogen, Janssen Biotech, and Boehringer Ingelheim for other services. Dr Nolte reports compensation from Daiichi Sankyo Europe GmbH, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, and Alexion Pharmaceuticals for consultant services; and compensation from AstraZeneca, Abbott Canada, Deutsches Zentrum für Neurodegenerative Erkrankungen, Novartis, Portola Pharmaceuticals, Deutsches Zentrum für Herz-Kreislaufforschung, and Novartis for other services. Dr Poppe reports grants from Foundation Brain Canada, Heart and Stroke Foundation of Canada, and Stryker; and compensation from Roche for other services. Dr Liebeskind reports compensation from Medtronic, Genentech, Cerenovus, Stryker, and Rapid Medical Ltd, for consultant services. B. Mac Grory reports grants from the National Institutes of Health; employment by Duke University Medical Center; compensation from Bayer for other services; grants from the American Heart Association, Duke Bass Connections, and the Duke Office of Physician Scientist Development. Dr Al Kasab reports compensation from Stryker for other services and employment by Medical University of South Carolina. Dr Kicielinski reports compensation from Stryker, Penumbra Inc, Medtronic, and MicroVention Inc, for other services; travel support from MicroVention Inc; and employment by Medical University of South Carolina and Elsevier. Dr de Havenon reports stock options in TitinKM and Certus; grants from the National Institutes of Health; and compensation from Novo Nordisk for consultant services. Dr Siegler reports grants from Philips and employment by the University of Chicago. Dr Willey reports compensation from Edwards Lifesciences Corporation and Abbott Fund for end point review committee services; compensation from Uptodate for other services; and compensation from the Abbott Laboratories for consultant services. Dr Sharma reports a provisional patent for a stroke etiology classifier algorithm and grants from the National Institutes of Health Clinical Center. Dr Martins reports compensation from Pfizer, Medtronic, Servier Affaires Medicales, Daiichi Sankyo, Bayer, Novo Nordisk, Novartis, Penumbra Inc, and Boehringer Ingelheim for other services. Dr Simpkins reports grants from the National Institutes of Health. Dr Stretz reports grants from Massachusetts General Hospital. Dr Furie reports compensation from Janssen Biotech for consultant services. The other authors report no conflicts- Published
- 2024
- Full Text
- View/download PDF
34. Endovascular Embolization of Traumatic Vessel Injury Using N-butyl Cyanoacrylate: A Case Series.
- Author
-
Morsi RZ, Baskaran A, Thind S, Carrión-Penagos J, Desai H, Kothari SA, Mirza M, Lazaridis C, Goldenberg F, Hurley MC, Mendelson SJ, Prabhakaran S, Zakrison T, Mansour A, and Kass-Hout T
- Abstract
There is limited evidence of N-butyl cyanoacrylate (n-BCA) use in endovascular embolization of traumatic face and neck vessel injuries. We investigated the safety and effectiveness of n-BCA for this purpose. We retrospectively analyzed consecutive patients presenting to a Level 1 trauma center between April 2021 and July 2022. We included patients aged ≥ 18 years old with any vessel injury in the face and neck circulation requiring n-BCA embolization. The primary endpoint was n-BCA effectiveness defined as immediate control of active bleeding post-embolization. In total, 13 patients met the inclusion criteria. The median decade of life was 3 (IQR 3 - 5) with a male predominance (n = 11, 84.6%). Median Glasgow Coma Scale score on presentation was 15 (IQR 3-15). Eleven patients suffered gunshot wound injuries; two patients suffered blunt injuries. Injured vessels included facial artery (n = 6, 46.2%), buccal branch artery (n = 3, 23.1%), internal maxillary (n = 5, 38.5%), cervical internal carotid artery (n = 1, 7.7%), and vertebral artery (n = 1, 7.7%). All patients were treated with 1:2 n-BCA to ethiodol mixture with immediate extravasation control. No bleeding recurrence or need for retreatment occurred. One patient died in-hospital (7.7%). Patients were discharged to home (n = 8, 61.5%), day rehabilitation (n = 1, 7.7%), or acute rehabilitation (n = 3, 23.1%). One patient developed a right posterior cerebral artery infarct with hemorrhagic transformation. To our knowledge, this is the first study demonstrating the safety and effectiveness of n-BCA liquid embolism in traumatic vessel injuries, especially penetrating gunshot wounds., Competing Interests: Conflict of interestThe authors declare no competing interests., (© Association of Otolaryngologists of India 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)
- Published
- 2024
- Full Text
- View/download PDF
35. Factors Affecting Selection of TraineE for Neurointervention (FASTEN).
- Author
-
Elfil M, Morsi RZ, Ghozy S, Elmashad A, Siddiqui A, Al-Bayati AR, Alaraj A, Brook A, Kam AW, Chatterjee AR, Patsalides A, Waldau B, Prestigiacomo CJ, Matouk C, Schirmer CM, Altschul D, Parrella DT, Toth G, Jindal G, Shaikh HA, Dolia JN, Fifi JT, Fraser JF, DO JT, Amuluru K, Kim LJ, Harrigan M, Amans MR, Kole M, Mokin M, Abraham M, Jumaa M, Janjua N, Zaidat O, Youssef PP, Khandelwal P, Wang QT, Grandhi R, Hanel R, Kellogg RT, Ortega-Gutierrez S, Sheth S, Nguyen TN, Szeder V, Hu YC, Yoo AJ, Tanweer O, Jankowitz B, Heit JJ, Williamson R, Kass-Hout T, Crowley RW, El-Ghanem M, and Al-Mufti F
- Abstract
Background and Importance: Neurointervention is a very competitive specialty in the United States due to the limited number of training spots and the larger pool of applicants. The training standards are continuously updated to ensure solid training experiences. Factors affecting candidate(s) selection have not been fully established yet. Our study aims to investigate the factors influencing the selection process., Methods: A 52-question survey was distributed to 93 program directors (PDs). The survey consisted of six categories: (a) Program characteristics, (b) Candidate demographics, (c) Educational credentials, (d) Personal traits, (e) Research and extracurricular activities, and (f) Overall final set of characteristics. The response rate was 59.1%. As per the programs' characteristics, neurosurgery was the most involved specialty in running the training programs (69%). Regarding demographics, the need for visa sponsorship held the greatest prominence with a mean score of 5.9 [standard deviation (SD) 2.9]. For the educational credentials, being a graduate from a neurosurgical residency and the institution where the candidate's residency training is/was scored the highest [5.4 (SD = 2.9), 5.4 (SD = 2.5), respectively]. Regarding the personal traits, assessment by faculty members achieved the highest score [8.9 (SD = 1)]. In terms of research/extracurricular activities, fluency in English had the highest score [7.2 (SD = 1.9)] followed by peer-reviewed/PubMed-indexed publications [6.4 (SD = 2.2)]., Conclusion: Our survey investigated the factors influencing the final decision when choosing the future neurointerventional trainee, including demographic, educational, research, and extracurricular activities, which might serve as valuable guidance for both applicants and programs to refine the selection process., Competing Interests: Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
36. The Zoom RDL radial access system for neurointervention: An early single-center experience.
- Author
-
Morsi RZ, Kothari SA, Thind S, Desai H, Polster SP, Goldenberg F, Coleman E, Brorson JR, Mendelson S, Mansour A, Prabhakaran S, and Kass-Hout T
- Subjects
- Humans, Male, Adult, Middle Aged, Aged, Female, Radial Artery diagnostic imaging, Radial Artery surgery, Thrombectomy methods, Catheters, Retrospective Studies, Treatment Outcome, Stroke diagnostic imaging, Stroke surgery, Embolization, Therapeutic
- Abstract
Background: The transradial approach (TRA) for neurointerventional procedures is increasingly being used given its technical feasibility and safety. However, catheter trackability and device deliverability are reported barriers to TRA adoption., Methods: This is the first report describing the technical feasibility and performance of using the Zoom RDL Radial Access System (Imperative Care, Inc., Campbell, CA) in 29 patients who underwent neurointerventional procedures from October 2022 to January 2023 in a single-center institution., Results: Mean age of the study population was 61.9±17.2 years, 79.3% were male (23/29), and 62.1% were black (18/29). The most common procedures were stroke thrombectomy (31.0%, 9/29) and aneurysm embolization (27.6%, 8/29). All the stroke thrombectomy procedures were successfully performed; first-pass effect rate (mTICI≥2 c in one pass) was achieved in 66.7% (6/9) of cases. We used TRA in 86.2% of cases (25/29), including distal radial/snuffbox access in 31.0% (9/29) of cases. The radial diameter was >2 mm for all cases. An intermediate/aspiration catheter was used in 89.7% (26/29) of cases. Access success was achieved in 89.7% of cases (26/29); two cases required conversion from TRA to transfemoral approach (6.9%) and one case required conversion to a different guide catheter (3.4%). There were no access site complications or other Zoom RDL-related complications. One intracerebral hemorrhage, and one procedure-related thrombus were observed., Conclusions: The use of Zoom RDL Radial Access System is technically feasible and effective for complex neurointerventional procedures with low complication rates., Competing Interests: Competing interests: TK – Brainomix: Consultant, Cerenovus: Consultant, Imperative Care: Consultant, Medtronic Inc.: Consultant, Microvention: Consultant, Stryker Neurovascular: Consultant. The remaining authors declared no competing interests., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
37. Randomized Secondary Prevention Trials in Participants With Symptomatic Intracranial Atherosclerotic Stenosis.
- Author
-
Dunn LE, Wang Y, Kass-Hout T, and Chiu D
- Subjects
- Humans, Secondary Prevention, Constriction, Pathologic, Cerebral Infarction, Ischemic Stroke, Stroke etiology, Stroke prevention & control, Intracranial Arteriosclerosis complications, Intracranial Arteriosclerosis surgery
- Abstract
Intracranial atherosclerotic stenosis is a prevalent cause of ischemic stroke worldwide. Its association with silent cerebral infarcts and its contribution to cognitive impairment and dementia emphasize the critical need for disease prevention and effective management strategies. Despite extensive research on secondary stroke prevention treatment over the past several decades, intracranial atherosclerotic stenosis continues to exhibit a notably higher recurrent stroke rate compared with other causes. This review focuses on randomized secondary prevention trials involving antithrombotic therapy, endovascular treatment, open surgical therapy, and remote ischemic conditioning. It aims to provide an insightful overview of the major findings from each trial and their implications for future research efforts., Competing Interests: Disclosures None.
- Published
- 2024
- Full Text
- View/download PDF
38. The use of PK Papyrus covered coronary stent for carotid reconstruction: an initial institutional experience.
- Author
-
Morsi RZ, Thind S, Chahine A, Zakaria J, Desai H, Kothari SA, Shah AP, Nathan S, Coleman E, Mendelson S, Siegler JE, Prabhakaran S, Mansour A, and Kass-Hout T
- Abstract
Background: The use of covered stent grafts for the treatment of carotid rupture is increasingly being used given their ability to preserve the parent artery while simultaneously occluding the fistula or rupture point., Methods: This case series describes the technical feasibility of using, and the performance of, the PK Papyrus covered coronary stent (Biotronik, Inc., Lake Oswego, Oregon, USA) in six patients with carotid rupture, including carotid cavernous fistulas, between July 2021 and October 2023 in a single-center institution in the USA., Results: The median decade of life was 5 (IQR 3) with a 1:1 male-to-female ratio. The majority were black patients (n=5/6, 83.3%). The most common disease pathology was carotid cavernous fistula (n=4/6, 66.7%), followed by traumatic carotid rupture (n=2/6, 33.3%). All the stent embolization procedures were successfully treated with the PK Papyrus covered coronary stent. None of the patients had any recurrence or re-treatment. The number of stents required ranged from 1 to 3. A balloon guide catheter was used in 66.7% of cases (n=4/6). In-hospital mortality was 0.0% (n=0/6). No in-stent thrombosis was observed, but there was one case of cangrelor-associated hemorrhagic stroke conversion. Transfemoral access was used in all cases with one access site complication. Median follow-up time was 1.8 months (IQR 3.5)., Conclusions: To our knowledge, this is the largest case series in the USA demonstrating the feasibility and safety of using the PK Papyrus covered coronary stent for the treatment of carotid rupture, including carotid cavernous fistulas., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
39. Endovascular Thrombectomy With or Without Thrombolysis for Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Author
-
Morsi RZ, Zhang Y, Carrión-Penagos J, Desai H, Tannous E, Kothari S, Khamis A, Darzi AJ, Tarabichi A, Bastin R, Hneiny L, Thind S, Coleman E, Brorson JR, Mendelson S, Mansour A, Prabhakaran S, and Kass-Hout T
- Abstract
Background: To this date, whether to administer intravenous thrombolysis (IVT) prior to endovascular thrombectomy (EVT) for stroke patients still stirs some debate. We aimed to systematically update the evidence from randomized trials comparing EVT alone vs EVT with bridging IVT., Methods: We searched MEDLINE, EMBASE, and the Cochrane Library to identify randomized controlled trials (RCTs) comparing EVT with or without IVT in patients presenting with stroke secondary to a large vessel occlusion. We conducted meta-analyses using random-effects models to compare functional independence, mortality, and symptomatic intracranial hemorrhage (sICH), between EVT and EVT with IVT. We assessed risk of bias using the Cochrane risk-of-bias tool and certainty of evidence for each outcome using the GRADE approach., Results: Of 11,111 citations, we included 6 studies with a total of 2336 participants. We found low-certainty evidence of possibly a small decrease in the proportion of patients with functional independence (risk difference [RD] -2.0%, 95% CI -5.9% to 2.0%), low-certainty evidence that there is possibly a small increase in mortality (RD 1.0%, 95% CI -2.2% to 4.7%), and moderate-certainty evidence that there is probably a decrease in sICH (RD -1.0%, 95% CI -1.6% to .7%) for patients with EVT alone compared to EVT plus IVT, respectively., Conclusion: Low-certainty evidence shows that there is possibly a small decrease in functional independence, low-certainty evidence shows that there is possibly a small increase in mortality, and moderate-certainty evidence that there is probably a decrease in sICH for patients with EVT alone compared to EVT plus IVT., Competing Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article., (© The Author(s) 2023.)
- Published
- 2024
- Full Text
- View/download PDF
40. Endovascular Thrombectomy with or without Bridging Thrombolysis in Acute Ischemic Stroke: A Cost-Effectiveness Analysis.
- Author
-
Morsi RZ, Zhang Y, Zhu M, Xie S, Carrión-Penagos J, Desai H, Tannous E, Kothari SA, Khamis A, Darzi AJ, Tarabichi A, Bastin R, Hneiny L, Thind S, Siegler JE, Coleman ER, Mendelson SJ, Mansour A, Prabhakaran S, and Kass-Hout T
- Subjects
- Humans, Thrombolytic Therapy, Cost-Effectiveness Analysis, Thrombectomy, Treatment Outcome, Cost-Benefit Analysis, Ischemic Stroke drug therapy, Ischemic Stroke surgery, Brain Ischemia drug therapy, Brain Ischemia surgery, Stroke drug therapy, Stroke surgery, Endovascular Procedures
- Abstract
Background: There is unclear added benefit of intravenous thrombolysis (IVT) with endovascular thrombectomy (EVT). We performed a cost-effectiveness analysis to assess the cost-effectiveness of comparing EVT with IVT versus EVT alone., Methods: We used a decision tree to examine the short-term costs and outcomes at 90 days after the occurrence of index stroke to compare the cost-effectiveness of EVT alone with EVT plus IVT for patients with stroke. Subsequently, we developed a Markov state transition model to assess the costs and outcomes over 1-year, 5-year, and 20-year time horizons. We estimated total and incremental cost, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio., Results: The average costs per patient were estimated to be $47,304, $49,510, $59,770, and $76,561 for EVT-only strategy and $55,482, $57,751, $68,314, and $85,611 for EVT with IVT over 90 days, 1 year, 5 years, and 20 years, respectively. The cost saving of EVT-only strategy was driven by the avoided medication costs of IVT (ranging from $8,178 to $9,050). The additional IVT led to a slight decrease in QALY estimate during the 90-day time horizon (loss of 0.002 QALY), but a small gain over 1-year and 5-year time horizons (0.011 and 0.0636 QALY). At a willingness-to-pay threshold of $50,000 per QALY gained, the probabilities of EVT only being cost-effective were 100%, 100%, and 99.3% over 90-day, 1-year, and 5-year time horizons., Conclusion: Our cost-effectiveness model suggested that EVT only may be cost-effective for patients with acute ischemic stroke secondary to large vessel occlusion., (© 2023 S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
41. Intravenous cangrelor use for neuroendovascular procedures: a two-center experience and updated systematic review.
- Author
-
Desai H, Al-Salihi MM, Morsi RZ, Vayani OR, Kothari SA, Thind S, Carrión-Penagos J, Baskaran A, Tarabichi A, Bonderski VA, Siegler JE, Hahn M, Coleman ER, Brorson JR, Mendelson SJ, Mansour A, Dabus G, Hurley M, Prabhakaran S, Linfante I, and Kass-Hout T
- Abstract
Background: The optimal antiplatelet therapy regimen for certain neuroendovascular procedures remains unclear. This study investigates the safety and feasibility of intravenous dose-adjusted cangrelor in patients undergoing acute neuroendovascular interventions., Methods: We conducted a retrospective chart review of all consecutive patients on intravenous cangrelor for neuroendovascular procedures between September 1, 2020, and March 13, 2022. We also conducted an updated systematic review and meta-analysis using PubMed, Scopus, Web of Science, Embase and the Cochrane Library up to February 22, 2023., Results: In our cohort, a total of 76 patients were included [mean age (years): 57.2 ± 18.2, males: 39 (51.3), Black: 49 (64.5)]. Cangrelor was most used for embolization and intracranial stent placement ( n = 24, 32%). Approximately 44% of our patients had a favorable outcome with a modified Rankin Scale (mRS) score of 0 to 2 at 90 days ( n = 25/57); within 1 year, 8% of patients had recurrent or new strokes ( n = 5/59), 6% had symptomatic intracranial hemorrhage [sICH] (4/64), 3% had major extracranial bleeding events (2/64), and 3% had a gastrointestinal bleed (2/64). In our meta-analysis, 11 studies with 298 patients were included. The pooled proportion of sICH and intraprocedural thromboembolic complication events were 0.07 [95% CI 0.04 to 1.13] and 0.08 [95% CI 0.05 to 0.15], respectively., Conclusion: Our study found that intravenous cangrelor appears to be safe and effective in neuroendovascular procedures, with low rates of bleeding and ischemic events. However, further research is needed to compare different dosing and titration protocols of cangrelor and other intravenous agents., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Desai, Al-Salihi, Morsi, Vayani, Kothari, Thind, Carrión-Penagos, Baskaran, Tarabichi, Bonderski, Siegler, Hahn, Coleman, Brorson, Mendelson, Mansour, Dabus, Hurley, Prabhakaran, Linfante and Kass-Hout.)
- Published
- 2023
- Full Text
- View/download PDF
42. Primary results from the CLEAR study of a novel stent retriever with drop zone technology.
- Author
-
Yoo AJ, Geyik S, Froehler MT, Maurer CJ, Kass-Hout T, Zaidat OO, Nogueira RG, Hanel RA, Pierot L, Spelle L, Lopes D, Hassan A, Širvinskas A, Lin E, Ribo M, Blasco J, Taqi MA, Badruddin A, Siddiqui AH, Miller TR, Hussain SM, Haussen DC, Woodward K, Groden C, Consoli A, Chaudry MI, Ramsey C, Maud A, Bentley J, Bajrami A, Sahnoun M, Fiehler J, and Gupta R
- Abstract
Background: Challenges to revascularization of large vessel occlusions (LVOs) persist. Current stent retrievers have limited effectiveness for removing organized thrombi. The NeVa device is a novel stent retriever designed to capture organized thrombi within the scaffold during retrieval., Objective: To evaluate the safety and effectiveness of revascularization of acute LVOs with the NeVa device., Methods: Prospective, international, multicenter, single-arm, Investigational Device Exemption study to evaluate the performance of the NeVa device in recanalizing LVOs including internal carotid artery, M1/M2 middle cerebral artery, and vertebrobasilar arteries, within 8 hours of onset. Primary endpoint was rate of expanded Treatment in Cerebral Ischemia (eTICI) score 2b-3 within 3 NeVa passes, tested for non-inferiority against a performance goal of 72% with a -10% margin. Additional endpoints included first pass success and 90-day modified Rankin Scale (mRS) score 0-2. Primary composite safety endpoint was 90-day mortality and/or 24-hour symptomatic intracranial hemorrhage (sICH)., Results: From April 2021 to April 2022, 139 subjects were enrolled at 25 centers. Median National Institutes of Health Stroke Scale (NIHSS) score was 16 (IQR 12-20). In the primary analysis population (n=107), eTICI 2b-3 within 3 NeVa passes occurred in 90.7% (97/107; non-inferiority P<0.0001; post hoc superiority P<0.0001). First pass eTICI 2b-3 was observed in 73.8% (79/107), with first pass eTICI 2b67-3 in 69.2% (74/107) and eTICI 2c-3 in 48.6% (52/107). Median number of passes was 1 (IQR 1-2). Final eTICI 2b-3 rate was 99.1% (106/107); final eTICI 2b67-3 rate was 91.6% (98/107); final eTICI 2c-3 rate was 72.9% (78/107). Good outcome (90-day mRS score 0-2) was seen in 65.1% (69/106). Mortality was 9.4% (13/138) with sICH in 5.0% (7/139)., Conclusions: The NeVa device is highly effective and safe for revascularization of LVO strokes and demonstrates superior first pass success compared with a predicate performance goal., Trial Registration Number: NCT04514562., Competing Interests: Competing interests: AJY: consultant: Penumbra, Cerenovus, Vesalio, Zoll Circulation, Philips Neurovascular; individual stocks/stock options: Nicolab; ownership interest: Insera Therapeutics, Galaxy Therapeutics; research funding (principal investigator (PI) or named investigator): Medtronic, Cerenovus, Penumbra, Stryker, Genentech. LS: consultant: Balt, Medtronic, Microvention, Stryker; research funding (PI or named investigator): Philips. AH: consultant: Medtronic, Microvention, Stryker, Penumbra, Cerenovus, Genentech, GE Healthcare, Scientia, Balt, Viz.ai, Insera therapeutics, Proximie, NeuroVasc, NovaSignal, Vesalio, Rapid Medical, Imperative Care. AS: consultant: Microvention, Stryker, Vesalio. AHS: consultant: Amnis Therapeutics, Apellis Pharmaceuticals, Inc., Boston Scientific, Canon Medical Systems USA, Inc., Cardinal Health 200, LLC, Cerebrotech Medical Systems, Inc., Cerenovus, Cerevatech Medical, Inc; inidividual stocks/stock options: Adona Medical, Inc., Amnis Therapeutics, Bend IT Technologies, Ltd., BlinkTBI, Inc, Borvo Medical, Inc., Cerebrotech Medical Systems, Inc., Cerevatech Medical, Inc., Cognition Medical, Collavidence, I; other; Cerenovus EXCELLENT and ARISE II Trial; Medtronic SWIFT PRIME, VANTAGE, EMBOLISE and SWIFT DIRECT Trials; MicroVention FRED Trial; CONFIDENCE Study; MUSC POSITIVE Trial; Penumbra 3D Separator Trial, Research Funding (PI or named investigator); co-investigator for NIH - 1R01EB030092-01, Project Title: High speed angiography at 1000 frames per second; Mentor for Brain Aneurysm Foundation Carol W. Harvey Chair of Research, Sharon Epperson Chai. SG: Consultant; Stryker, Microvention, Medtronic. TRM: Advisor; Carpl AI. MTF: advisor; Cerenovus; research funding (PI or named investigator): Medtronic Neurovascular; researcher: Stryker Neurovascular, Cerenovus, Rapid Medical. DCH: consultant; Stryker Neurovascular, Cerenovus, Chiesi USA, Brainomix, Poseydon Medical; individual stocks/stock options: VizAI and Motif; other: Jacobs Institute/Medtronic, Vesalio., Frontiers in Neurology. MIC: advisor: Celt/Vasorum; consultant: Microvention, Medtronic, Imperative Care, Q'Apel; individual stocks/stock options: Imperative Care, Celt/Vasorum, Synchron, Endostream, Cerebrotech, Q'Apel, RIST, Three Rivers Medical, Neuolutions, Radical Medical, Tulavi, viseon, VMT, Vastrax, Serenity Medical. MF: consultant: Cerenovus, Balt, Jacobs Institute, Kai Medical, Oculus; research funding (PI or named investigator): Vesalio, Genentech, Siemens. MS: consultant: Vesalio., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
43. An alternative reduced dose regimen of ticagrelor for neuroendovascular patients.
- Author
-
Kass-Hout O, Stern J, D Tangonan R, Morsi RZ, Thind S, Kass-Hout T, and Guterman L
- Subjects
- Humans, Clopidogrel pharmacology, Hemorrhage chemically induced, Retrospective Studies, Treatment Outcome, Platelet Aggregation Inhibitors adverse effects, Ticagrelor adverse effects
- Abstract
Objective: There is a growing use of ticagrelor in patients undergoing neuroendovascular procedures, especially those who demonstrate clopidogrel resistance. While multiple dosages are studied in the cardiology literature, the optimal dose for patients with neurological pathology has yet to be established. Here, we describe a single center experience involving 39 patients who underwent neuroendovascular procedures that then received an adjusted lower dose of ticagrelor., Methods: A retrospective chart review was performed between 2013 and 2017 for patients on dual anti-platelet therapy (DAPT) for either cervical or intracranial vascular pathologies, as well as stenting of the neurovasculature, including carotid arteries. Patients were placed on ticagrelor if their measured P2Y
12 reaction units (PRU) responses to clopidogrel were outside the expected range in our center using the VerifyNow™ P2Y12 test. All patients were maintained on a dose of 45 mg twice daily except for one patient who received 22.5 mg twice daily. Responsiveness to ticagrelor were measured utilizing the VerifyNow™ P2Y12 test., Results: The mean number of days for follow-up post treatment initiation was 532 days. A total of 39 patients were included in the analysis. Of these, 8 patients (21%) received implantation of intracranial stents (5 patients received pipeline embolization devices, 1 patient received stent-assisted coiling, and 2 patients received intracranial stents for atherosclerotic disease). Fourteen patients (35%) received carotid angioplasty and stenting. Seventeen patients (44%) did not receive permanent implantation of a stent. All patients on the lower dose ticagrelor of 45 mg twice daily achieved responsiveness (i.e., PRU < 194). Hemorrhagic transformation of ischemic stroke occurred in one patient (2.5%). No other hemorrhagic complications were encountered. No thromboembolic events were recorded aside from one patient (2.5%) with intracranial atherosclerotic disease who had an ischemic event., Conclusions: A lower dose of ticagrelor (45 mg twice daily) appears to be safe and effective in this small cohort of patients who are resistant to clopidogrel per P2Y12 testing and who have increased risk of ischemic or hemorrhagic strokes due to neurovascular pathologies and implants. Further randomized studies are required to confirm these findings., Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.- Published
- 2023
- Full Text
- View/download PDF
44. Safety and efficacy of tirofiban in the management of stroke: A systematic review and meta-analysis of randomized controlled trials.
- Author
-
Al-Salihi MM, Ayyad A, Al-Jebur MS, Al-Salihi Y, Saha R, Morsi RZ, Kass-Hout T, Kasab SA, and Spiotta AM
- Subjects
- Humans, Tirofiban adverse effects, Platelet Aggregation Inhibitors adverse effects, Treatment Outcome, Randomized Controlled Trials as Topic, Intracranial Hemorrhages chemically induced, Intracranial Hemorrhages complications, Brain Ischemia complications, Stroke complications
- Abstract
Background: About 30 % of stroke patients have experienced unsuccessful reperfusion following endovascular therapy. Mechanical thrombectomy instruments may contribute to this by stimulating platelet aggregation. Tirofiban is a selective and rapidly activated antagonist of the platelets nonpeptide glycoprotein IIb/IIIa receptors that can reversibly suppress platelet aggregation. But, data from the medical literature are conflicting regarding its safety and efficacy for stroke patients. Hence, this study was designed to assess the safety and efficacy of tirofiban in stroke patients., Methods: Five major databases (PubMed, Scopus, Web of Science, Embase, and Cochrane library) were searched till December 2022. The Cochrane tool was used for risk of bias assessment, and the RevMan 5.4 was utilized for data analysis., Results: Seven RCTs with 2088 stroke patients were included. Tirofiban significantly increased the number of patients with mRS 0 score after 90 days than control; RR= 1.39, 95 %CI [1.15, 1.69]; p = 0.0006. Additionally, it reduced the NIHSS score after seven days; MD= -0.60, 95 %CI [-1.14, -0.06]; p = 0.03. However, tirofiban increased the incidence of intracranial haemorrhage (ICH); RR= 1.22, 95 %CI [1.03, 1.44]; p = 0.02. Other assessed outcomes showed insignificant results., Conclusions: Tirofiban was associated with a higher mRS 0 score after three months and a lower NIHSS score after seven days. However, it is associated with higher ICH. Multicentric trials are required to provide more convincing proof of its utility., Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
45. Real-World Outcomes for Basilar Artery Occlusion Thrombectomy With Mild Deficits: The National Inpatient Sample.
- Author
-
Patel K, Taneja K, Obusan MB, Yaghi S, Nguyen TN, Thon JM, Kass-Hout T, Brorson JR, Prabhakaran S, and Siegler JE
- Subjects
- Adult, Humans, Basilar Artery, Treatment Outcome, Inpatients, Thrombectomy adverse effects, Retrospective Studies, Stroke surgery, Stroke diagnosis, Arterial Occlusive Diseases surgery, Endovascular Procedures adverse effects
- Abstract
Background: Thrombectomy for basilar artery occlusion (BAO) has proven efficacy in patients with moderate-to-severe deficits, but has unclear benefits for those with mild symptoms., Methods: Using an observational cohort design, the US National Inpatient Sample (2018-2020) was queried for adult patients with basilar artery occlusion and National Institutes of Health Stroke Scale (NIHSS) <10 for patients treated with thrombectomy versus medical management. The primary outcome of routine discharge (to home or self-care) was evaluated using multivariable logistic regression and propensity score matching, adjusted for baseline characteristics, stroke severity, and treatment with thrombolysis., Results: Of 17 019 with basilar artery occlusion, 5795 patients met the criteria for inclusion criteria for our study, and 880 (15.4%) were treated with endovascular thrombectomy. In the propensity score-matched cohort, 880 patients were treated with medical management and endovascular thrombectomy, respectively. In multivariable regression, endovascular thrombectomy was associated with both an increased odds of routine discharge (odds ratio, 1.95 [95% CI, 1.31-2.90]; P =0.001) and a decreased length of hospital stay (B, -0.74 [95% CI, -1.36 to -0.11]; P =0.02) compared with medical management. In the propensity score matched cohort, endovascular thrombectomy remained associated with greater odds of routine discharge (2.01 [95% CI, 1.21-3.34]; P =0.007) but no difference in length of hospital stay (B, -0.22 [95% CI, -0.90 to 0.46]; P =0.53)., Conclusions: Routine discharge was more common in this representative US cohort of patients with basilar artery occlusion and National Institutes of Health Stroke Scale <10 who underwent thrombectomy compared to conventional medical management. These findings suggest thrombectomy may be associated with better functional outcomes despite lower National Institutes of Health Stroke Scale and should be validated in a clinical trial setting., Competing Interests: Disclosures Dr Nguyen reports research support from SVIN and Medtronic; advisory board with Idorsia. S. Yaghi reports research support from Medtronic. Dr Prabhakaran reports research support from National Institute of Neurological Disorders and Stroke, Agency for Healthcare Research and Quality; royalties from UpToDate; consultant fees from Wolters Kluwer Health Inc. The other authors report no conflicts.
- Published
- 2023
- Full Text
- View/download PDF
46. Embolization in Juvenile Nasopharyngeal Angiofibroma Surgery: A Systematic Review and Meta-Analysis.
- Author
-
Diaz A, Wang E, Bujnowski D, Arimoto R, Armstrong M, Cyberski T, Nordgren R, Seal SM, Kass-Hout T, and Roxbury C
- Subjects
- Humans, Bayes Theorem, Neoplasm Recurrence, Local, Angiofibroma surgery, Nasopharyngeal Neoplasms surgery, Embolization, Therapeutic methods
- Abstract
Objective: To compare outcomes of juvenile nasopharyngeal angiofibroma (JNA) resection between embolized and non-embolized cohorts, and between transarterial embolization (TAE) and direct puncture embolization (DPE)., Data Sources: Per PRISMA guidelines, PubMed, Embase, Web of Science, Scopus, and Cochrane databases were searched for publications prior to or in 2021., Materials and Methods: Original English manuscripts investigating the resection of JNA with and without preoperative embolization were included. Embolization type, recurrence rate, complication rates, blood loss, and transfusions were extracted. Risk of bias was assessed by the Risk of Bias in Non-randomized Studies-of Interventions method., Results: There were 61 studies with 917 patients included. Preoperative embolization was performed in 79.3% of patients. Of those embolized, 75.8% (N = 551) underwent TAE and 15.8% (N = 115) underwent DPE. JNA recurrence in embolized patients was lower than in non-embolized patients (9.3% vs. 14.4%; odds ratio [OR]: 0.61, 95% confidence interval [CI]: 0.35, 1.06). DPE resulted in lower rates of disease recurrence (0% vs. 9.5%; OR: 0.066, 95% CI: 0.016, 0.272) and complications (1.8% vs. 21.9%; OR: 0.07, 95% CI: 0.02, 0.3) than TAE. A random effects Bayesian model was performed to analyze the difference in mean blood loss in 6 studies that included both embolized and non-embolized patients. This analysis showed a mean reduction in blood loss of 798 mL in the embolized group., Conclusions: We found embolization decreases blood loss in JNA resection. DPE led to improved recurrence and complication rates when compared to TAE, but future prospective studies are needed to further evaluate which embolization technique can optimize outcomes in JNA., Level of Evidence: NA Laryngoscope, 133:1529-1539, 2023., (© 2023 The Authors. The Laryngoscope published by Wiley Periodicals LLC on behalf of The American Laryngological, Rhinological and Otological Society, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
47. Endovascular thrombectomy with or without thrombolysis bridging in patients with acute ischaemic stroke: protocol for a systematic review, meta-analysis of randomised trials and cost-effectiveness analysis.
- Author
-
Morsi RZ, Zhang Y, Carrión-Penagos J, Desai H, Tannous E, Kothari S, Khamis AM, Darzi AJ, Tarabichi A, Bastin R, Hneiny L, Thind S, Coleman E, Brorson JR, Mendelson S, Mansour A, Prabhakaran S, and Kass-Hout T
- Subjects
- Adult, Humans, Adolescent, Cost-Effectiveness Analysis, Thrombectomy, Thrombolytic Therapy, Systematic Reviews as Topic, Brain Ischemia, Stroke, Ischemic Stroke
- Abstract
Introduction: Current published guidelines and meta-analyses comparing endovascular thrombectomy (EVT) alone versus EVT with bridging intravenous thrombolysis (IVT) suggest that EVT alone is non-inferior to EVT with bridging thrombolysis in achieving favourable functional outcome. Because of this controversy, we aimed to systematically update the evidence and meta-analyse data from randomised trials comparing EVT alone versus EVT with bridging thrombolysis, and performed an economic evaluation comparing both strategies., Methods and Analysis: We will conduct a systematic review of randomised controlled trials comparing EVT with or without bridging thrombolysis in patients presenting with large vessel occlusions. We will identify eligible studies by systematically searching the following databases from inception without any language restrictions: MEDLINE (through Ovid), Embase and the Cochrane Library. The following criteria will be used to assess eligibility for inclusion: (1) adult patients ≥18 years old; (2) randomised patients to EVT alone or to EVT with IVT; and (3) measured outcomes, including functional outcomes, at least 90 days after randomisation. Pairs of reviewers will independently screen the identified articles, extract information and assess the risk of bias of eligible studies. We will use the Cochrane Risk-of-Bias tool to evaluate risk of bias. We will also use the Grading of Recommendations, Assessment, Development and Evaluation approach to assess the certainty in evidence for each outcome. We will then perform an economic evaluation based on the extracted data., Ethics and Dissemination: This systematic review will not require a research ethics approval because no confidential patient data will be used. We will disseminate our findings by publishing the results in a peer-reviewed journal and via presentation at conferences., Prospero Registration Number: CRD42022315608., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
48. Endovascular Thrombectomy for Large Ischemic Strokes: A Living Systematic Review and Meta-Analysis of Randomized Trials.
- Author
-
Morsi RZ, Elfil M, Ghaith HS, Aladawi M, Elmashad A, Kothari S, Desai H, Prabhakaran S, Al-Mufti F, and Kass-Hout T
- Abstract
Background and Purpose: New studies have shown that endovascular thrombectomy (EVT) is safe and effective for acute ischemic stroke (AIS) patients with large ischemic areas. The aim of our study is to conduct a living systematic review and meta-analysis of randomized trials comparing EVT versus medical management only., Methods: We searched MEDLINE, Embase, and the Cochrane Library to identify randomized controlled trials (RCTs) comparing EVT versus medical management alone in AIS patients with large ischemic regions. We conducted our meta-analysis using fixed-effect models to compare functional independence, mortality, and symptomatic intracranial hemorrhage (sICH) between EVT and standard medical management only. We assessed the risk of bias using the Cochrane risk-of-bias tool and the certainty of evidence for each outcome using the Grading of Recommendations, Assessment, Development, and Evaluations approach., Results: Of 14,513 citations, we included 3 RCTs with a total of 1,010 participants. We found low-certainty evidence of possibly a large increase in the proportion of patients with functional independence (risk difference [RD] 30.3%, 95% CI 15.0% to 52.3%), low-certainty evidence of possibly a small non-significant decrease in mortality (RD -0.7%, 95% CI -3.8% to 3.5%), and low-certainty evidence of possibly a small non-significant increase in sICH (RD 3.1%, 95% CI -0.3% to 9.8%) for AIS patients with large infarcts who underwent EVT compared to medical management only., Conclusion: Low-certainty evidence shows that there is possibly a large increase in functional independence, a small non-significant decrease in mortality, and a small non-significant increase in sICH amongst AIS patients with large infarcts undergoing EVT compared to medical management only.
- Published
- 2023
- Full Text
- View/download PDF
49. Endovascular thrombectomy for cerebral venous sinus thrombosis using the Penumbra Indigo ® Aspiration System.
- Author
-
Kothari S, Morsi RZ, Thind S, Tarabichi A, Carrión-Penagos J, Desai H, Smith M, Goldenberg F, Mansour A, Ahmed O, Coleman ER, Mendelson S, Prabhakaran S, and Kass-Hout T
- Abstract
We present a 35-year-old male with ulcerative colitis initially admitted for a flare-up who then presented with altered mental status and was found to have extensive cerebral venous sinus thrombosis on computed tomography imaging. The patient underwent successful partial recanalization of the superior sagittal sinus and bilateral transverse sinuses using the Penumbra Indigo® Aspiration System with improved outcomes. To our knowledge, this is the first reported use of this device in the treatment of cerebral venous sinus thrombosis.
- Published
- 2023
- Full Text
- View/download PDF
50. Review Paper on Penetrating Brain Injury: Ethical Quandaries in the Trauma Bay and Beyond.
- Author
-
Zakrison TL, Essig R, Polcari A, McKinley W, Arnold D, Beyene R, Wilson K, Rogers S Jr, Matthews JB, Millis JM, Angelos P, O'Connor M, Mansour A, Goldenberg F, Spiegel T, Horowitz P, Das P, Slidell M, Chokshi N, Okeke I, Barth R, Wilkins HE 3rd, Kass-Hout T, and Lazaridis C
- Subjects
- Humans, Child, Resuscitation methods, Neurosurgical Procedures, Head Injuries, Penetrating, Brain Injuries, Traumatic, Tissue and Organ Procurement
- Abstract
Objective: The aim of this review was to review the ethical and multidisciplinary clinical challenges facing trauma surgeons when resuscitating patients presenting with penetrating brain injury (PBI) and multicavitary trauma., Background: While there is a significant gap in the literature on managing PBI in patients presenting with multisystem trauma, recent data demonstrate that resuscitation and prognostic features for such patients remains poorly described, with trauma guidelines out of date in this field., Methods: We reviewed a combination of recent multidisciplinary evidence-informed guidelines for PBI and coupled this with expert opinion from trauma, neurosurgery, neurocritical care, pediatric and transplant surgery, surgical ethics and importantly our community partners., Results: Traditional prognostic signs utilized in traumatic brain injury may not be applicable to PBI with a multidisciplinary team approach suggested on a case-by-case basis. Even with no role for neurosurgical intervention, neurocritical care, and neurointerventional support may be warranted, in parallel to multicavitary operative intervention. Special considerations should be afforded for pediatric PBI. Ethical considerations center on providing the patient with the best chance of survival. Consideration of organ donation should be considered as part of the continuum of patient, proxy and family-centric support and care. Community input is crucial in guiding decision making or protocol establishment on an institutional level., Conclusions: Support of the patient after multicavitary PBI can be complex and is best addressed in a multidisciplinary fashion with extensive community involvement., Competing Interests: The authors report no conflicts of interest., (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.